Compass Pathways (NASDAQ: CMPS) Begins Trading on Nasdaq Global Select Market

Last Friday, psychedelic drug company Compass Pathways (NASDAQ: CMPS) began trading on the Nasdaq Global Select Market. Its shares surged 70.6% and closed at $29.00. This lifted the market cap to almost $1 billion. The launch comes after Compass Pathways reportedly upsized pricing for its IPO. The company is backed by Peter Thiel, PayPal cofounder and billionaire investor.

Compass Pathways is a London-based company that is studying hallucinogenic mushrooms as a therapeutic. The company’s IPO was $17 per share, which was an increase from the initial $14-$16 expectation that had been announced earlier in the week. This put the valuation…


About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.